Related Experiment Video
Updated: Apr 11, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Maintenance therapy in non-small cell lung cancer
Giovenzio Genestreti1, Monica Di Battista, Giovanna Cavallo
1Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy.
Maintenance therapy for advanced non-small cell lung cancer (NSCLC) offers benefits but requires careful consideration of toxicity and cost. Identifying patient subgroups who benefit most is crucial for personalized treatment strategies.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Advanced non-small cell lung cancer (NSCLC) patients not progressing after first-line chemotherapy with good performance status are candidates for maintenance therapy.
- Two main strategies exist: switch maintenance (non-cross-resistant drugs) and continuation maintenance (platinum-based).
Purpose of the Study:
- To review randomized trials on maintenance treatment in advanced NSCLC.
- To discuss the impact of maintenance therapy on clinical practice, considering toxicity and costs.
- To identify patient subgroups who may benefit from specific maintenance strategies.
Main Methods:
- Systematic review of randomized controlled trials investigating maintenance therapy in advanced NSCLC.
- Analysis of treatment strategies: switch maintenance, continuation maintenance, and combination maintenance.
- Evaluation of clinical practice implications, including toxicity and cost-effectiveness.
Main Results:
- Maintenance therapy can improve outcomes for selected advanced NSCLC patients.
- Different strategies (switch vs. continuation) offer distinct benefit profiles.
- Toxicity and cost are critical factors influencing treatment decisions and clinical adoption.
Conclusions:
- Maintenance therapy is a viable option for advanced NSCLC patients post-first-line chemotherapy.
- Personalized selection based on patient characteristics and specific therapy benefits is essential.
- Further research should focus on identifying predictive biomarkers for optimal maintenance strategy selection.
More Related Videos
11:17Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...